Drugs / Aggrenox
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | AGGRENOX | — | 1999-11-22 | fda.gov ↗ |
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT00311402 | Apr 2006 → Mar 2009 | stroke disorder | Boehringer Ingelheim | Completed | Missed primary |
| Phase 3 | NCT00067119 | Jan 2003 → Jan 2008 | kidney failure | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00274586 | Sep 2002 → Apr 2003 | stroke disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02251184 | Oct → Nov 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01455935 Comparator | Nov 2011 → Dec 2013 | stroke disorder | Jacobs Neurological Institute | Unknown | No outcome recorded |
| — | NCT00738894 Background | Dec 2008 → Apr 2017 | transient ischemic attack | W.L.Gore & Associates | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-02-03 | Boehringer Ingelheim | Results Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI prnewswire.com ↗
Boehringer Ingelheim presented results of a drug interaction study that found Aggrenox® (aspirin/extended-release dipyridamole), an antiplatelet medication, is not affected by the co-administration of omeprazole, a proton pump inhibitor (PPI), frequently used to treat several gastrointestinal conditions. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-02-03 | Boehringer Ingelheim | Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI prnewswire.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aggrenox | “3. Aggrenox 225mg PO twice daily” NCT01455935 ↗ |
| Route | Oral | “Aggrenox 225mg PO twice daily” NCT01455935 ↗ |